|Articles|March 16, 2021
- Pharmaceutical Technology-03-15-2021
- Volume 2021 eBook
- Issue 1
Can FDA Reinvent Inspections
Author(s)Agnes Shanley
A plant inspection backlog caused by COVID-19 restrictions threatens innovation and public health. Now pressured to step up on-site inspections, will FDA embrace new methods?
Advertisement
Pressure is mounting on FDA to step up the pace of on-site inspections that were postponed due to COVID-19 safety issues and restrictions. An open question is whether the agency will use new remote auditing technologies to improve its ability to inspect facilities during the COVID-19 pandemic.
Article details
Pharmaceutical Technology
eBook: Regulatory Sourcebook, March 2021
March 2021
Pages: 4-5
Citation
When referring to this article, please cite it as A. Shanley, “Can FDA Reinvent Inspections,” Pharmaceutical Technology Regulatory Sourcebook eBook (March 2021).
Articles in this issue
over 4 years ago
It Takes a Bio/Pharma Villageover 4 years ago
Managing the Risk of Nitrosamine Impuritiesover 4 years ago
Collaborative Efforts Address Key Data Integrity Challengesover 4 years ago
FDA 2021 Guidance Agenda Sees Focus on Genericsover 4 years ago
A Real-World Approach to Evaluating Cleanroom Garmentsover 4 years ago
Resources, Guidelines, and Guidance Documents Directoryover 4 years ago
Regulatory and Standard Setting Organizations DirectoryNewsletter
Get the essential updates shaping the future of pharma manufacturing and compliance—subscribe today to Pharmaceutical Technology and never miss a breakthrough.
Advertisement
Related Content
Advertisement
Advertisement
